argenx将以最高11.5亿美元收购Unnatural Products，以推进下一代药物研发-动脉网

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

GlobeNewswire 等信源发布 2026-11-09 06:00



可切换为仅中文







Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion

Argenx将以5.5亿美元的首付款收购UNP，并附加与开发和监管里程碑挂钩的或有价值权，总潜在价值高达约11.5亿美元

Acquisition builds on the two-year multi-target research collaboration

此次收购建立在为期两年的多目标研究合作基础之上

UNP’s team and macrocycle platform to continue as argenx’s dedicated macrocyclic peptide discovery hub in Santa Cruz

UNP 的团队和大环平台将继续作为 argenx 在圣克鲁斯的大环肽发现专属中心

SANTA CRUZ, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) --

加利福尼亚州圣克鲁斯，2026年11月9日（环球新闻网）——

Unnatural Products, Inc.

非自然产品有限公司

(UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced that it has entered into a definitive agreement to be acquired by argenx (Euronext & Nasdaq: ARGX), a global immunology company.

(UNP) 是一家开发生物大环肽类口服药物以解决此前难以成药靶点的生物科技公司，今日宣布已与全球免疫学公司 argenx（泛欧交易所及纳斯达克股票代码：ARGX）签订最终收购协议。

Under the terms of the agreement, argenx will acquire all of the outstanding equity of UNP for total potential value of up to approximately $1.15 billion. Upon closing, UNP will continue operating from its Santa Cruz site as part of argenx's global research organization, expanding argenx's discovery capabilities and further strengthening its innovation engine.

根据协议条款，argenx将收购UNP的全部未偿股权，总潜在价值高达约11.5亿美元。交易完成后，UNP将继续在其圣克鲁斯基地运营，作为argenx全球研究组织的一部分，从而扩展argenx的研发发现能力，并进一步强化其创新引擎。

Closing is expected by year-end, subject to customary closing conditions..

预计将于年底前完成交割，但须满足惯例交割条件。

“Today is a tremendous milestone for UNP and a testament to the exceptional work of our scientists, employees, collaborators and supporters,” said Cameron Pye, Ph.D., CEO and Co-Founder of UNP. “From the earliest days, we believed our platform had the potential to redefine what is possible in the discovery and design of new medicines.

“今天对UNP而言是一个巨大的里程碑，也证明了我们科学家、员工、合作伙伴和支持者们的卓越工作。”UNP首席执行官兼联合创始人Cameron Pye博士表示，“从最初开始，我们就相信我们的平台有潜力重新定义新药发现与设计的可能性。”

I am so proud of what our team has accomplished and believe argenx provides the ideal environment to accelerate and amplify that vision to bring innovative therapies to patients.”.

我为我们团队所取得的成就深感自豪，并相信 argenx 提供了理想的环境，以加速并放大这一愿景，从而为患者带来创新疗法。

“Our ambition is to be the leading immunology innovation company, and as argenx builds its next chapter, we are investing with discipline where it will count the most for patients,” said Karen Massey, Chief Executive Officer of argenx. “UNP adds macrocyclic peptide capabilities that are highly complementary to our antibody engineering and creates new possibilities for oral and long-acting medicines.

argenx 首席执行官 Karen Massey 表示：“我们的雄心是成为领先的免疫学创新公司。在 argenx 谱写新篇章之际，我们正以严谨的态度在对患者最具价值的领域进行投资。UNP 为大环肽技术带来了高度互补的能力，与我们的抗体工程技术相得益彰，并为口服和长效药物开辟了新的可能性。”

After working together for more than two years, we also know there is a strong fit in how we work: science first, entrepreneurial and focused on patients. We want to preserve what has made UNP successful while bringing the strengths of both teams together.”.

在合作两年多之后，我们也深知双方在工作方式上高度契合：坚持科学优先、秉持创业精神、以患者为中心。我们希望将两支队伍的优势融合在一起，同时保留使UNP取得成功的核心要素。

Macrocyclic peptides combine the precision and efficacy of biologics with the convenience of oral dosing and can reach intracellular targets that have long been out of the range of conventional drugs. Over the past 10 years, UNP has built an integrated discovery platform that pairs AI-guided design with massively parallel synthesis and direct-to-biology screening, allowing the company to repeatedly engineer drug-like macrocycles at scale..

大环肽兼具生物制剂的精准性与高效性，以及口服给药的便利性，能够作用于长期处于传统药物作用范围之外的细胞内靶点。在过去十年中，UNP 构建了一个集成发现平台，将人工智能引导的设计与大规模平行合成及直接生物学筛选相结合，使公司能够大规模地反复设计出具有药物特性的大环分子。

UNP was founded in 2016 by Dr. Pye and Chief Scientific Officer, Joshua Schwochert, Ph.D., during the final year of their doctoral research in Dr. Scott Lokey’s lab at the University of California, Santa Cruz. They believed the industry was overlooking the therapeutic potential of macrocyclic peptides and started the company in Schwochert’s garage.

UNP 由 Pye 博士和首席科学官 Joshua Schwochert 博士于 2016 年创立，当时他们正在加州大学圣克鲁兹分校 Scott Lokey 博士的实验室进行博士研究的最后一年。他们认为业界忽视了大环肽的治疗潜力，于是在 Schwochert 的车库中创办了这家公司。

UNP has since become a leading platform company in the macrocyclic peptide field. It has secured four major pharmaceutical partnerships in under five years. The company, still proudly based in Santa Cruz, now employs more than 50 people..

UNP 已成为大环肽领域领先的平台型公司，在不到五年的时间内达成了四项重大制药合作伙伴关系。该公司仍以总部位于圣克鲁斯为荣，目前员工人数已超过 50 人。

Added Dr. Schwochert, “This is the result of years of scientific innovation and tenacious execution by an extraordinary team. UNP has had real momentum in recent years based on strong investor support and multiple partnerships. While we evaluated multiple options for growing as a company, argenx brought a shared belief in the science, a strong cultural fit, and a commitment to preserving the innovative spirit that helped build our platform.

Schwochert 博士补充道：“这是由一支非凡的团队经过多年科学创新和坚韧执行所取得的成果。近年来，在投资者的大力支持和多项合作伙伴关系的推动下，UNP 取得了切实的发展势头。在我们评估公司增长的多种方案时，argenx 不仅与我们对科学有着共同的信念，文化契合度高，还承诺保留帮助我们构建平台的那种创新精神。

We are excited about staying true to our roots in Santa Cruz while exploring what we can accomplish together.”.

我们既为坚守在圣克鲁斯的根基而兴奋，也为探索我们能够共同实现的成就而充满期待。

About Unnatural Products

关于非自然产品

Unnatural Products, Inc. (UNP), a California biotech company, has developed a platform that addresses the complexities of medicinal chemistry in the macrocyclic peptide space through a combination of parallel experimentation and machine learning. Founded by macrocycle pioneers whose academic work uncovered how Nature’s macrocycles work, UNP is developing a portfolio of therapeutic macrocycles against high-value and traditionally difficult-to-drug targets.

Unnatural Products, Inc.（UNP）是一家位于加州的生物技术公司，其开发了一个平台，通过并行实验与机器学习相结合，应对大环肽领域药物化学的复杂性。UNP由大环化合物领域的先驱创立，这些创始人的学术研究揭示了天然大环化合物的作用机制。目前，UNP正在开发一系列治疗性大环化合物，针对高价值且传统上难以成药的靶点。

Alongside their multi-target collaboration with argenx, UNP has partnerships with Novartis, Merck, and BridgeBio. For more information, visit .

除了与argenx在多靶点方面的合作外，UNP还与诺华、默克和BridgeBio建立了合作伙伴关系。欲了解更多信息，请访问。

www.unnaturalproducts.com

。

Contacts

联系人

Company Contact:

公司联系人：

Andrew Stevens

安德鲁·史蒂文斯

Unnatural Products

非天然产物